Results 31 to 40 of about 21,405,282 (107)
Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1525-1534, September 2026.Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.Glenn Geidel, Sabrina Bänsch, Laura Adam, Nathan Fekade, Alessandra Rünger, Tim Zell, Daniel J. Smit, Julian Kött, Isabel Heidrich, Michael Weichenthal, Selma Ugurel, Ulrike Leiter, Peter Mohr, Alexandra Geusau, Stephan Grabbe, Markus V. Heppt, Ralf Gutzmer, Jochen Utikal, Jan‐Christoph Simon, Sebastian Haferkamp, Laura Susok, Bastian Schilling, Edgar Dippel, Imke von Wasielewski, Jessica C. Hassel, Carola Berking, Stefan W. Schneider, Christoffer Gebhardt +27 morewiley +1 more sourceResponse‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort
British Journal of Haematology, Volume 209, Issue 2, Page 524-533, August 2026.Summary
Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...Farina Eigendorff, Fabian Görke, Vanja Zeremski, Sophia Wollnitza, Evgenii Shumilov, Georg Lenz, Ellen Obstfelder, Inken Hilgendorf, Vladan Vučinić, Andreas Hochhaus, Ulf Schnetzke +10 morewiley +1 more sourceAddiction and chronic skin diseases: A Pan‐European study on prevalence, associations and patient impact
Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 8, Page 1392-1405, August 2026.This pan‐European study reveals high rates of addiction in patients with chronic skin diseases. Smoking, alcohol, drug use, gambling, and internet addiction were prevalent and associated with quality of life, demographics, and region. The findings support integrating addiction screening into dermatologic care to improve outcomes.Stefanie Ziehfreund, Magdalena Saak, Alisa Schaal, Roxana Mazilu, Emmanuel Mahé, Carla Hajj, Emma K. Johansson, Josefin Lysell, Gunnthorunn Sigurdardottir, Franz J. Legat, Catherina Koch, Astrid Schmieder, Caroline Glatzel, Brian Kirby, Emily Pender, Anna Zalewska‐Janowska, Katarzyna Tomaszewska, Giulia Ciccarese, Pia Lauriola, Michael J. Boffa, Stephanie Farrugia, Anna Caroline Pilz, Franziska Schauer, Magdalena Trzeciak, Weronika Zysk, Krisztián Gáspár, Andrea Szegedi, Giovanni Damiani, Andrea Carugno, Ilona Hartmane, Ingmars Mikazans, Skaidra Valiukeviciene, Livija Petrokaite, Jacek C. Szepietowski, Beata Jastrząb, Petra Staubach, Suzana Ljubojević Hadžavdić, Daška Štulhofer Buzina, Christian Posch, Jakob Jochmann, Antonia Wiala, Ludwig Scheffenbichler, Emanuele Trovato, Laura Calabrese, Gyula Laszlo Fekete, Pavel Chernyshov, Lidiia Kolodzinska, Julia Welzel, Karisa Thölken, Julia‐Tatjana Maul, Lara Valeska Maul, Damian Meyersburg, Stephanie Bowe, Cathal O. Connor, Razvigor Darlenski, Stephan Traidl, Christian Vestergaard, Elena Lucía Pinto‐Pulido, Maria Polina Konstantinou, Eszter Szlávicz, Kristine Heidemeyer, Nikhil Yawalkar, Hanka Agnes Caroline Lantzsch, Aleksandra Soplinska, Anna‐Theresa Seitz, Tiago Torres, Zenon Brzoza, Ana Sanader Vučemilović, Liana Manolache, Nina Magnolo, Emanuele Scala, Kilian Eyerich, Tilo Biedermann, Alexander Zink +73 morewiley +1 more sourceReal‐world management of adjuvant systemic melanoma therapy: Multi‐center survey of 51 DeCOG skin cancer centers
JDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 24, Issue 7, Page 916-926, July 2026.Summary Background
Adjuvant immune checkpoint inhibitors (ICI) and targeted therapy (TT) have revolutionized treatment management for patients with melanoma. However, the current German S3 guideline does not differentiate between patients with and without adjuvant therapy in its recommendations for imaging intervals and follow‐up monitoring, leading to Markus Reitmajer, Elisabeth Livingstone, Lucie Heinzerling, Kai‐Martin Thoms, Frank Meiss, Markus V. Heppt, Anja Gesierich, Konstantin Drexler, Friedegund Meier, Max Schlaak, Andrea Forschner, Lisa Zimmer +11 morewiley +1 more sourceMelanoma Brain Metastasis, Prognostic Factors, and Survival Outcomes After First Metastatic Line Therapy: A Monocentric Retrospective Study
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT
Brain metastases (BMs) are a major cause of mortality in patients with melanoma. We conducted a retrospective observational study to identify prognostic factors for BM development and to evaluate the impact of first‐line systemic therapy on BM occurrence and survival outcomes in patients with advanced melanoma.Hadi Srour, Emmanuel Chamorey, Aram Hovhannisyan, Alexandra Picard‐Gauci, Laura Troin, Perrine Rousset, Fabien Almairac, Emmanuelle Pradelli, Jérôme Doyen, Elodie Long‐Mira, Micheline Razzouk‐Cadet, Madleen Chassang, Thierry Passeron, Henri Montaudié +13 morewiley +1 more sourceCharacterization of long‐term survivors with liver metastases from uveal melanoma diagnosed between 2005 and 2021
International Journal of Cancer, Volume 158, Issue 8, Page 2179-2185, 15 April 2026.What's New?
Liver metastasis is an indicator of life expectancy for patients with advanced uveal melanoma (UM). Data on anticipated survival time following the diagnosis of liver metastasis, however, is lacking. The present study analyzed long‐term survival among UM patients who lived three or more years after liver metastases were diagnosed.Jona Laukhuf, Lisa Wiens, Gerd Grözinger, Helmut Dittmann, Karolin Thiel, Ulrike Leiter, Teresa Amaral, Lena Nanz, Lukas Flatz, Markus Reitmajer, Andrea Forschner +10 morewiley +1 more sourceBridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival
British Journal of Haematology, Volume 208, Issue 4, Page 1347-1358, April 2026.Summary
Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT) Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti +28 morewiley +1 more source